OJCD  Vol.3 No.4 , December 2013
Development and evaluation of an ELISA method for the measurement of kallikrein-related peptidase 5 (KLK5) in human serum
Abstract: Kallikrein-related peptidases (KLKs) have been proposed as potential cancer biomarkers. Kallikrein-related peptidase 5 (KLK5) is a secreted trypsin-like protease of the KLKs. Until now, detection of KLK5 in both biological fluids and tissues has been described frequently due to the potential of being a new cancer biomarker. Our objective was to prepare KLK5 antibodies and establish an ELISA method for KLK5 to study the possible clinical application of KLK5 as a biomarker for malignancies. In this study, recombinant KLK5 protein was produced and purified using a prokaryotic expression system, and then used as immunogen to generate antibodies. High titers of specific antibodies were measured in serum of rabbits after the forth booster injection. And the titer of the antiserum reached 1:106. We have also generated monoclonal antibodies using hybridoma technology and the titer reached 1:105. The activity of KLK5 antibodies was characterized by Western blot and immunohistochemistry. To quantitatively examine KLK5 in serum samples, we established double antibody sandwich ELISA method using mouse mAb as capture and rabbit pAb as tracer antibody. We have detected KLK5 levels in ovarian cancer serum to ensure that our sandwich ELISA measurement to have high sensitivity and specificity. The ranges of linearity reached by the standard curves of the newly developed ELISA were 0.45 ng/mL to 125 ng/mL. The detection limit of the method, defined as the concentration of KLK5 can be distinguished, was 0.20 ng/mL. Median serum KLK5 levels were 3.77 ng/mL and 0.86 ng/mL in ovarian cancer patients and normal female, respectively (P < 0.001). In conclusion, we prepare anti-KLK5 antibodies and develop the sandwich-type ELISA assay for KLK5. Our preliminary findings prompt that KLK5 may be a new potential biomarker for the diagnosis and prognosis in patients with ovarian.
Cite this paper: Wu, Y. , Liu, X. , Chen, Y. and Hu, C. (2013) Development and evaluation of an ELISA method for the measurement of kallikrein-related peptidase 5 (KLK5) in human serum. Open Journal of Clinical Diagnostics, 3, 159-166. doi: 10.4236/ojcd.2013.34029.

[1]   Yousef, G.M. and Diamandis, E.P. (2001) The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocrine Reviews, 22, 184-204.

[2]   Yousef, G.M., Chang, A., Scorilas, A. and Diamandis, E.P. (2000) Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochemical and Biophysical Research Communications, 1, 125-133.

[3]   Yousef, G.M., Luo, L.Y. and Diamandis, E.P. (1999) Identification of novel human hallidrein-like genes on chromosome 19q13.3-19q13.4. Anticancer Research, 19, 2843-2852.

[4]   Yousef, G.M. and Diamandis, E.P. (2000) Human kallikreins: Common structural features, sequence analysis and evolution. Current Genomics, 4, 147-165.

[5]   Borgono, C.A., Michael, I.P. and Diamandis, E.P. (2004) Human tissue kallikreins: Physiologic roles and applications in cancer. Molecular Cancer Research, 2, 257-280.

[6]   Paliouras, M. and Diamandis, E.P. (2006) The kallikrein world: An update on the human tissue kallikreins. Biological Chemistry, 6, 643-652.

[7]   Paliouras, M. and Diamandis, E.P. (2007) Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Research and Treatment, 1, 7-18.

[8]   Diamandis, E.P., Yousef, G.M., Luo, L.Y., Magklara, A. and Obiezu, C.V. (2000) The new human kallikrein gene family: Implications in carcinogenesis. Trends in Endocrinology & Metabolism, 2, 54-60.

[9]   Yousef, G.M. and Diamandis, E.P. (1999) The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. Journal of Biological Chemistry, 53, 37511-37516.

[10]   Brattsand, M. and Egelrud, T. (1999) Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. Journal of Biological Chemistry, 42, 30033-30040.

[11]   Michael, I.P., Pampalakis, G., Mikolajczyk, S.D., Malm, J., Sotiropoulou, G. and Diamandis, E.P. (2006) Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. Journal of Biological Chemistry, 18, 12743-12750.

[12]   Michael, I.P., Sotiropoulou, G., Pampalakis, G., Magklara, A., Ghosh, M., Wasney, G. and Diamandis, E.P. (2005) Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. Journal of Biological Chemistry, 15, 14628-14635.

[13]   Kim, H., Scorilas, A., Katsaros, D., Yousef, G.M., Massobrio, M., Fracchioli, S., Piccinno, R., Gordini, G. and Diamandis, E.P. (2001) Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. British Journal of Cancer, 5, 643-650.

[14]   Yousef, G.M., Scorilas, A., Kyriakopoulou, L.G., Rendl, L., Diamandis, M., Ponzone, R., Biglia, N., Giai, M., Roagna, R., Sismondi, P. and Diamandis, E.P. (2002) Human kallikrein gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor prognosis in breast cancer. Clinical Chemistry, 8, 1241-1250.

[15]   Yousef, G.M., Obiezu, C., Jung, K., Stephan, C., Scorilas, A. and Diamandis, E.P. (2002) Differetial expression of kallikrein gene 5 (KLK5) in cancerous and normal testicular tissues. Urology, 4, 714-718.

[16]   Yousef, G.M., Polymeris, M.E., Grass, L., Soosaipillai, A., Chan, P.C., Scorilas, A., Borgono, C., Harbeck, N., Schmalfeldt, B., Dorn, J., Schmitt, M. and Diamandis, E.P. (2003) Human Kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer. Cancer Research, 14, 3958-3965.

[17]   Shaw, J.L. and Diamandis, E.P. (2007) Distribution of 15 human kallikreins in tissues and biological fluids. Clinical Chemistry, 8, 1423-1432.

[18]   Diamandis, E.P., Borgono, C.A., Scorilas, A., Yousef, G.M., Harbeck, N., Dorn, J., Schmalfeldt, B. and Schmitt, M. (2003) Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumor Biology, 6, 299-309.

[19]   Ekholm, I.E., Brattsand, M. and Egelrud, T. (2000) Stratum corneumtryptic enzyme in normal epidermis: A missing link in the desquamation process. Journal of Investigative Dermatology, 1, 56-63.

[20]   Komatsu, N., Takata, M., Otsuki, N., Toyama, T., Ohka, R., Takehara, K. and Saijoh, K. (2003) Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. Journal of Investigative Dermatology, 3, 542-549.

[21]   Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., Egelrud, T., Simon, M. and Serre, G. (2004) Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/ KLK5/hK5 and SCCE/KLK7/hK7. Journal of Investigative Dermatology, 5, 1235-1244.

[22]   Ishida-Yamamoto, A., Deraison, C. and Bonnart, C. (2005) LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. Journal of Investigative Dermatology, 2, 360-366.

[23]   Bast, R.C., Hennessy, B. and Mills, G.B. (2009) The biology of ovarian cancer: New opportunities for translation. Nature Reviews Cancer, 6, 415-428.

[24]   Jacobs, J. and Bast, R.C. (1989) The CA125 tumor associated antigen: A review of the literature. Human Reproduction, 4, 1-12.

[25]   Borgono, C.A. and Diamandis, E.P. (2004) The emerging roles of human tissue kallikreins in cancer. Nature Reviews Cancer, 11, 876-890.

[26]   Dorn, J., Magdolen, V., Gkazepis, A., Gerte, T. and Harlozinska, A. (2011) Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients’ survival. Annals of Oncology, 8, 1783-1790.

[27]   Bandiera, E., Zanotti, L., Bignotti, E., Romani, C., Tassi, R. and Todeschini, P. (2009) Human kallikrein 5 an interesting novel biomarker in ovarian cancer patients that elicits humoral response. International Journal of Gynecological Cancer, 6, 1015-1021.